Breast Cancer Clinical Trials in Utah

76 recruiting studies across 12 cities

All Trials in Utah

Phase
Trial Phase Location
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3American Fork
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/AAmerican Fork
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3Farmington
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3Farmington
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3Farmington
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Phase 3Murray
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Phase 3Murray
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPhase 3Ogden
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles—Ogden
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast CancerPhase 2Salt Lake City
A Phase 1 Study of LNCB74 in Advanced Solid TumorsPhase 1Salt Lake City
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerPhase 3Salt Lake City
A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsPhase 1Salt Lake City
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePhase 3Salt Lake City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsPhase 1/2Salt Lake City
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerPhase 2Salt Lake City
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsPhase 1Salt Lake City
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationPhase 3Salt Lake City
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesPhase 1/2Salt Lake City
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Phase 3Salt Lake City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Phase 3Salt Lake City
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsPhase 1Salt Lake City
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerPhase 1/2Salt Lake City
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)Phase 1/2Salt Lake City
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.Phase 3Salt Lake City
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseasePhase 3Salt Lake City
Community Services Navigation to Advance Health Equity in Breast Cancer ScreeningN/ASalt Lake City
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With CancerN/ASalt Lake City
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentPhase 2Salt Lake City
Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations StudyN/ASalt Lake City
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound SystemEarly 1Salt Lake City
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerPhase 1Salt Lake City
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBCPhase 2Salt Lake City
Guided Meditation During Radiation Therapy for Breast and Gynecological MalignanciesPhase 3Salt Lake City
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPhase 2Salt Lake City
Improving Care for Rural Patients With Solid TumorsN/ASalt Lake City
Increasing Germline Genetic Testing for Patients With CancerN/ASalt Lake City
JAB-2485 Activity in Adult Patients With Advanced Solid TumorsPhase 1/2Salt Lake City
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on EnhertuPhase 2Salt Lake City
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation—Salt Lake City
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerPhase 3Salt Lake City
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With PembrolizumabPhase 1/2Salt Lake City
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerPhase 3Salt Lake City
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsPhase 3Salt Lake City
SAVE Trial: SAfe Opioid Use Video EducationN/ASalt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—Salt Lake City
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsPhase 1/2Salt Lake City
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3Salt Lake City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialPhase 3Salt Lake City
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer SurvivorsN/ASalt Lake City
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.Phase 1/2Salt Lake City
A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerPhase 1West Valley City
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPhase 1West Valley City
A Phase 1/1b Study of IAM1363 in HER2 CancersPhase 1West Valley City
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsPhase 1/2West Valley City
A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsPhase 1West Valley City
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPhase 1/2West Valley City
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesPhase 1West Valley City
A Study of LY4175408 in Participants With Advanced CancerPhase 1West Valley City
A Study of MGC026 in Participants With Advanced Solid TumorsPhase 1West Valley City
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid TumorsPhase 1West Valley City
A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPhase 1West Valley City
A Study of Sofe-M in Participants With Selected Advanced Solid TumorsPhase 1West Valley City
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsPhase 1West Valley City
A Study to Evaluate ATX-898 in Participants With Advanced Solid TumorsPhase 1/2West Valley City
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsPhase 1West Valley City
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsPhase 1West Valley City
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsPhase 1West Valley City
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsPhase 1/2West Valley City
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast CancerPhase 1West Valley City
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsPhase 1West Valley City
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid TumorsPhase 1/2West Valley City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Phase 1/2West Valley City
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast CancerPhase 1West Valley City
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanPhase 1West Valley City
Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsPhase 1/2West Valley City

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.